Treatment Information

Back

Colon Cancer treatment details. Chemotherapy, Biologic therapy.

Hopital Tenon, Paris, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Paris
Treatments:Chemotherapy, Biologic therapyHospital:Hopital Tenon
Drugs:Journal:Link
Date:Jan 2007

Description:

Patients: This phase II study involved 42 patients with metastatic colorectal cancer. Twenty-four were men and 18 were women, and the median age was 60, ranging from 31-76. 67% had stage IV disease.

Treatment: All 42 patients received celecoxib (a non-steroidal anti-inflammatory drug) and the chemotherapy drugs 5FU (Fluorouracil) and oxaliplatin, and folinic acid.

Toxicity: There were two episodes of grade 4 toxicity; vomiting and thrombocytopenia. Grade 3 toxicities reported were nausea, diarrhea, peripheral neuropathy, neutropenia and thrombocytopenia.

Results: Median overall survival was 15.8 months. Thirty-five patients stopped the study for progression, toxicity, personal choice, or the investigator’s decision

Support: This study was supported by a grant from Pfizer. Pfizer makes celecoxib and markets it as Celebrex®

Correspondence: Dr. T. Andre



Back